tobramycin has been researched along with epidermal growth factor in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, Y; Hirata, Y; Kobayashi, Y; Kojima, T; Ono, A; Watanabe, K | 1 |
| Beckers, JF; Falmagne, P; Heuson-Stiennon, JA; Laurent, G; Leonard, I; Nonclercq, D; Schaudies, RP; Toubeau, G; Zanen, J | 1 |
| Ding, XJ; Li, Y; Shao, MY; Song, HQ; Xu, FJ | 1 |
3 other study(ies) available for tobramycin and epidermal growth factor
| Article | Year |
|---|---|
Maturational changes and origin of urinary human epidermal growth factor in the neonatal period.
Topics: Age Factors; Asphyxia Neonatorum; Birth Weight; Epidermal Growth Factor; Female; Humans; Infant, Newborn; Infant, Premature; Kidney Function Tests; Male; Tobramycin | 1989 |
Modification of immunoreactive EGF and EGF receptor after acute tubular necrosis induced by tobramycin or cisplatin.
Topics: Analysis of Variance; Animals; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Female; Immunohistochemistry; Kidney; Kidney Tubular Necrosis, Acute; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Tobramycin | 1994 |
Multifunctional Delivery Nanosystems Formed by Degradable Antibacterial Poly(Aspartic Acid) Derivatives for Infected Skin Defect Therapy.
Topics: Animals; Anti-Bacterial Agents; Biocompatible Materials; Drug Delivery Systems; Epidermal Growth Factor; Fibroblasts; Humans; Male; Mice; Nanostructures; NIH 3T3 Cells; Peptides; Pseudomonas aeruginosa; Rabbits; Rats, Wistar; Skin; Staphylococcal Skin Infections; Staphylococcus aureus; Tobramycin; Wound Healing | 2019 |